The MTH1 level in the karonudib treated group after tumor re-growth was unchanged compared to the control group (Supplemental Fig. 6C) suggesting that tumor cells after relapse still could be sensitive to karonudib treatment. This evidence concerns the gene NUDT1 and neoplasm.